Description
Teoxane Teosyal RHA 4
Teosyal® RHA 4 is a CE‑marked, resilient hyaluronic acid (HA) dermal filler developed by Teoxane Laboratories (Switzerland) for professional aesthetic use in deep volume restoration and correction of moderate to severe dynamic facial wrinkles and folds. RHA stands for Resilient Hyaluronic Acid, a patented HA formulation designed with a low degree of modification (MoD ~3.6‑4 %) that preserves longer HA chains and supports natural tissue movement while maintaining structural support. This gel combines 23 mg/mL cross‑linked HA with 0.3 % lidocaine for enhanced patient comfort during injection. Its rheological profile provides a combination of elasticity and strength suited for deep dermal to subcutaneous placement in areas with significant volume loss or dynamic expression, including the cheeks, chin, jawline, and other contour regions. RHA 4 integrates smoothly with tissue and adapts to facial motion over extended durations, commonly reported between 9–22 months depending on patient factors and treatment area.
What Teosyal® RHA 4 Is Similar To
Teosyal® RHA 4 is functionally comparable to other deep volume HA fillers such as Juvederm® Voluma and Restylane® Lyft in that all provide structural volume augmentation and deep fold correction via cross‑linked hyaluronic acid. Like these products, RHA 4 is designed for deep dermal or subcutaneous placement to restore midface volume and support facial contours. However, RHA technology’s lower degree of HA modification is intended to maintain longer polymer chains with improved dynamic resilience, allowing the gel to adapt to facial expressions and motion with fewer rigid constraints. In contrast, standard high‑modification HA gels may offer stronger lift at the cost of stiffness. Longevity for deep HA fillers generally ranges from 9–18+ months, with RHA 4 often cited toward the higher end depending on anatomical site and patient metabolism. This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
-
Mid‑ to lower face volume restoration (e.g., cheeks, cheekbones)
-
Chin and jawline contouring
-
Correction of moderate to severe dynamic wrinkles such as nasolabial folds and marionette lines
-
Extended dynamic facial areas where elasticity and movement are significant
Usage / Administration (IFU‑only section)
Publicly available IFU data for precise injection parameters is limited; the following reflects verified manufacturer/distributor information where available. Where direct IFU parameters are not publicly provided, “not provided by manufacturer” is stated.
-
Injection depth: Deep dermis to subcutaneous plane, adapted to anatomical requirements of target area.
-
Volume per point / injection site: Not provided by manufacturer
-
Needle gauge: 27 G × ½″ sterile needles included.
-
Frequency / number of sessions: Not provided by manufacturer
-
Professional‑use disclaimer: Administered only by qualified medical professionals under aseptic conditions.
Some practitioners adopt multilayering techniques for midface volumisation; this is not included in the official IFU.
Ingredient List
-
Hyaluronic Acid (HA): 23 mg/mL cross‑linked hyaluronic acid of non‑animal origin
-
Lidocaine Hydrochloride: 0.3 % for injection comfort
-
Phosphate buffer: stabilising excipient to maintain pH compatibility
Presentation & Longevity
-
Packaging: 2 × 1.2 ml pre‑filled syringes, 2 × 27 G × ½″ needles, traceability labels, and product insert.
-
Shelf life: Not provided by manufacturer
-
Treatment duration / longevity: Effects commonly reported to last between 9–22 months, dependent on the anatomical site and individual metabolism.
Safety Notes / Contraindications
-
Use is contraindicated in patients with hypersensitivity to hyaluronic acid, lidocaine, or any component.
-
Not for use in areas with active skin infections, inflammation, or compromised tissue integrity.
-
Avoid treatment in pregnant or breastfeeding individuals.
-
Should not be combined with concurrent aggressive resurfacing procedures (e.g., peels, lasers) at the same site.
Regulatory Status
-
CE‑marked Class III medical device compliant with EU Medical Device Regulation (MDR).
-
Regulatory classification not specified in public documentation; verify on product pack or manufacturer’s IFU.
FAQ
1. What is Teosyal® RHA 4?
Teosyal® RHA 4 is a resilient hyaluronic acid dermal filler designed for deep volumisation and contouring of facial structures. It uses patented RHA technology with a balanced cross‑linked HA formulation to provide elasticity and strength for dynamic facial areas while supporting natural expression. It contains lidocaine for improved patient comfort during clinical injection.
2. How does the RHA technology differ from traditional HA fillers?
RHA technology minimises excessive cross‑linking of HA chains, preserving longer HA polymers that are more adaptable to facial movements. This can result in a filler that integrates smoothly with tissues and maintains elasticity, compared with traditional highly cross‑linked HA gels that may prioritise lift over pliability.
3. Where can Teosyal® RHA 4 be used?
It is typically used in areas requiring deep volume restoration such as cheeks, chin, jawline, and regions with moderate to severe dynamic wrinkles. Placement is generally in the deep dermis to subcutaneous plane, administered by a qualified clinician.
4. How long do results last?
While individual outcomes vary, clinical and distributor information suggests visible volumising effects may persist 9–22 months after treatment, with longevity influenced by treatment area, metabolism, and lifestyle.
5. Is it safe?
When used by trained professionals under aseptic technique, RHA 4 is generally well tolerated. Common, transient side effects include swelling, redness, or tenderness at injection sites. Contraindications include hypersensitivity to components and active infections.
